CSBio CSBio

X
[{"orgOrder":0,"company":"Biomay","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Biomay"},{"orgOrder":0,"company":"Fresenius Kabi USA, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Fresenius Kabi USA, LLC"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Noxafil-Generic (posaconazole) is a CYP451 inhibitor drug, which is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older and candida infections.

            Lead Product(s): Posaconazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Noxafil-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Biomay is one of the manufacturers supplying BioNTech with the DNA template for the in-vitro transcription of their mRNA active ingredient. The manufacturing agreement was initiated during the clinical development phase of the Comirnaty vaccine in Q1/2020.

            Lead Product(s): Tozinameran

            Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 17, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY